Official Title
STUDY OF THE APPEARANCE OF LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION
Brief Summary

Prospective, observational, multicenter study that will evaluate the changes in lung function that patients admitted with SARS-CoV-2 pneumonia will present according to the level of severity at 4, 12, 26 and 52 weeks after hospital discharge.

Detailed Description

The project consists of a prospective, observational, multicenter study that will evaluate
changes in lung function (forced spirometry, measurement of static lung volumes using
plethysmography and pulmonary carbon monoxide diffusion test) that patients admitted with
pneumonia will present. caused by SARS-CoV-2 according to the level of severity at 4, 12, 26
and 52 weeks after discharge from hospital. Restrictive pulmonary abnormalities will be
confirmed by imaging tests (high resolution chest CT).

Unknown status
Pulmonary Fibrosis
Eligibility Criteria

Inclusion Criteria:

- Patients admitted for bilateral pneumonia caused by SARS-CoV-2 (confirmed by PCR).

- Age over 18 years.

- Acceptance of informed consent.

- Life expectancy over 1 year.

Exclusion Criteria:

- Patients with a previous diagnosis of interstitial lung disease.

- Inability to attend review visits.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 90 Years
Countries
Spain
Locations

Pulmonary Department. Hospital Clinico.
Valencia, Spain

Investigator: Jaime Signes-Costa, MD, PhD
Contact: 34 961973500
jaimesignescosta@gmail.com

Fundación para la Investigación del Hospital Clínico de Valencia
NCT Number
MeSH Terms
COVID-19
Pulmonary Fibrosis